First Trust Advisors LP increased its holdings in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 235.6% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 114,946 shares of the biotechnology company’s stock after purchasing an additional 80,696 shares during the quarter. First Trust Advisors LP owned 0.15% of Momenta Pharmaceuticals worth $2,127,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of MNTA. BlackRock Inc. increased its position in Momenta Pharmaceuticals by 64,825.8% during the 1st quarter. BlackRock Inc. now owns 8,774,070 shares of the biotechnology company’s stock worth $117,134,000 after purchasing an additional 8,760,556 shares in the last quarter. State Street Corp grew its position in Momenta Pharmaceuticals by 30.8% in the first quarter. State Street Corp now owns 2,455,449 shares of the biotechnology company’s stock valued at $32,776,000 after acquiring an additional 577,504 shares in the last quarter. Acadian Asset Management LLC grew its position in Momenta Pharmaceuticals by 322.9% in the second quarter. Acadian Asset Management LLC now owns 696,138 shares of the biotechnology company’s stock valued at $11,762,000 after acquiring an additional 531,525 shares in the last quarter. Renaissance Technologies LLC grew its position in Momenta Pharmaceuticals by 186.4% in the second quarter. Renaissance Technologies LLC now owns 797,400 shares of the biotechnology company’s stock valued at $13,476,000 after acquiring an additional 519,000 shares in the last quarter. Finally, FMR LLC grew its position in Momenta Pharmaceuticals by 3.3% in the second quarter. FMR LLC now owns 11,125,193 shares of the biotechnology company’s stock valued at $188,015,000 after acquiring an additional 351,743 shares in the last quarter. 93.68% of the stock is owned by hedge funds and other institutional investors.

Several brokerages have issued reports on MNTA. Stifel Nicolaus reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Momenta Pharmaceuticals in a research report on Thursday, August 3rd. J P Morgan Chase & Co reaffirmed a “hold” rating and issued a $14.00 price objective on shares of Momenta Pharmaceuticals in a research report on Thursday, October 5th. BidaskClub downgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, August 22nd. Goldman Sachs Group Inc began coverage on shares of Momenta Pharmaceuticals in a research report on Thursday, September 28th. They issued a “neutral” rating and a $18.00 price objective for the company. Finally, ValuEngine downgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, October 6th. Three investment analysts have rated the stock with a sell rating and nine have issued a hold rating to the company. The company presently has an average rating of “Hold” and an average target price of $15.00.

Momenta Pharmaceuticals, Inc. (MNTA) opened at $13.80 on Friday. Momenta Pharmaceuticals, Inc. has a one year low of $11.85 and a one year high of $19.90.

Momenta Pharmaceuticals (NASDAQ:MNTA) last released its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.44) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.47) by $0.03. The company had revenue of $24.09 million during the quarter, compared to analysts’ expectations of $29.58 million. Momenta Pharmaceuticals had a negative return on equity of 16.20% and a negative net margin of 55.61%. The business’s revenue was down 17.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.26) EPS. research analysts forecast that Momenta Pharmaceuticals, Inc. will post -1.16 EPS for the current year.

In other news, President Craig A. Wheeler sold 35,667 shares of the stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $19.03, for a total transaction of $678,743.01. Following the completion of the transaction, the president now directly owns 286,121 shares in the company, valued at approximately $5,444,882.63. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Over the last quarter, insiders have sold 64,373 shares of company stock valued at $1,135,608. Company insiders own 4.40% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Momenta Pharmaceuticals, Inc. (MNTA) Shares Bought by First Trust Advisors LP” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://www.watchlistnews.com/momenta-pharmaceuticals-inc-mnta-shares-bought-by-first-trust-advisors-lp/1726968.html.

Momenta Pharmaceuticals Profile

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.